Shares of Mural Oncology (MURA) skyrocketed 134% on Tuesday after the company announced its decision to discontinue all clinical development of nemvaleukin alfa and plans to immediately commence the exploration of strategic alternatives focused on maximizing shareholder value. The company will also slash its workforce by 90%.Mural Oncology is considering various strategic options, such as a potential sale of the business, merger, or other transactions. Although there is no set timeline for this process, the ...